List of few peptide and drug combinations found helpful in combatting microbial infections
| Peptide(s) | Combined compound(s) | Bacterial specie(s) | Testing models | Concentrations | Synergism | Reference |
|---|---|---|---|---|---|---|
| CRAMP | Vancomycin | Salmonella enterica serovar Typhimurium | Clinical (in-vitro) | - | Yes | [184] |
| DJK-5 and DJK-6 | Ciprofloxacin, ceftazidime, tobramycin | Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa | Clinical (in-vitro) | 0.8 µg/mL of DJK-5 and DJK-6 | Yes | [185] |
| AMP38 | Imipenem | Pseudomonas aeruginosa | Clinical (in-vitro) | 62.5 µg/mL of AMP38 plus imipenem | Yes | [186] |
| HPMA | Ciprofloxacin | Acinetobacter baumannii | Clinical (in-vitro) | 25 µM of HPMA, 400 µM of ciprofloxacin | Yes | [187] |
| Lactoferrin | Ciprofloxacin | Porphyromonas gingivalis | In vivo | 10 μg/mL of ciprofloxacin, 8 mg/mL of lactoferrin | Yes | [188] |
| Nisin | Penicillin | Enterococcus faecalis | Clinical (in-vitro) | 31.25 U/mL of nicin, 0.0625 mg/L of penicillin | Yes | [111] |
| Nisin | DHBA | Staphylococcus aureus | Clinical (in-vitro) | 50 mg/mL of DHBA, 15 mg/mL of nisin | Yes | [189] |
| hBD-3 | DNase I | Haemophilus influenzae | In vivo (chinchillas) | 0.5 g (r)hBD-3/mL, 0.5 g enzyme/mL sBHI | Yes | [190] |
| KSL-W | Dispersin B | Acinetobacter baumanii, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis | Clinical (in-vitro) | 1 mg/mL of KSL-W, 0.2 mg/mL of dispersin B | Yes | [191] |
| Temporin 1Tb | EDTA | Staphylococcus epidermidis | Clinical (in-vitro) | 2 mg/mL of temporin 1Tb, 50 mM (18.6 mg/mL) of EDTA | Yes | [192] |
| hBD-2 | NO, colistin, chloramphenicol | Pseudomonas aeruginosa | Clinical (in-vitro) | 1.5 flux NO, 20 μg/mL AMP, 100 μg/mL antibiotics | Yes | [193] |
| DD13 | RNA III-inhibiting peptide | Staphylococcus aureus, Staphylococcus epidermidis | In vivo (rat) | 10 mg/L of DD13, RNA III-inhibiting peptide | Yes | [194] |
| Citropin 1.1, temporin A, an analog of tachyplesin I | Colistin | Pseudomonas aeruginosa, Staphylococcus aureus | Clinical (in-vitro) | 32 mg/L of colistin, 1 mg/mL of citropin 1.1, 4 mg/L of temporin A | Yes | [195] |
| Nisin | Colistin, polymyxin B | Pseudomonas aeruginosa | Clinical (in-vitro) | 100 µM of nisin, 128 or 256 µg/mL of colistin, polymyxin B | Yes | [196] |
AMP: antimicrobial peptide; hBD: human beta-defensin; NO: nitric oxide. Adapted with permission from [197], © 2017 the authors (CC BY)
The supplementary Table for this article is available at: https://www.explorationpub.com/uploads/Article/file/1008110_sup_1.pdf.
The authors acknowledge Dr. Chandru Subramani, who provided valuable insights during the manuscript preparation.
RD and GKC: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. N Priyadarshi and MB: Validation, Writing—review & editing. N Parmar: Writing—review & editing. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not Applicable.
Not Applicable.
Not Applicable.
Not Applicable.
Not Applicable.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.